Table 1.
Incidence of CNS metastases among ovarian carcinoma patients, interval between diagnosis of ovarian carcinoma and CNS metastases, survival after diagnosis of ovarian carcinoma, and survival after diagnosis of CNS metastases.
| Author (year) [ref.] | Study period | Number of patients with OC | Number of patients with CNS metastases (%) | Median Interval between diagnosis of OC and CNS metastases in months (range) | Median survival after diagnosis of OC in months (range) | Median survival after diagnosis of CNS metastases in months (range) |
|---|---|---|---|---|---|---|
| Mayer et al. (1978) [13] | 1973–1977 | NA | 6 | 26 (2–82) | 38 (8–85+) | 4.5 (2–33+) |
| Barker et al. (1981) [24] | 1969–1979 | 430 | 4 (0.9) | 34 (11–72) | 37 (13–78) | 4 (0.2–8) |
| Budd et al. (1983) [25] | 1978–1980 | 42 | 3 (7.1) | 19 (19–20) | NA | NA |
| Larson et al. (1986) [20] | 1944–1984 | 4,456 | 13 (0.29) | NA | 26 | 5 |
| Stein et al. (1986) [26] | 1979–1985 | 110 | 5 (4.5) | 17 (16–43) | 28 (18–43) | 2 (1–11) |
| Dauplat et al. (1987) [27] | 1973–1983 | 255 | 5 (1.96) | 25 (10–126) | 24 (11–135) | 1 (1–10) |
| Ziegler et al. (1987) [28] | 1983–1985 | NA | 5 | 11 (11–31) | NA | 8 (1–9+) |
| Ross et al. (1988) [29] | 1980–1984 | 342 | 7 (2) | NA | 27 (12–52) | 6.5 (2–26) |
| Hardy and Harvey (1989) [30] | 1981–1984 | 52 | 6 (11.6) | 28.5 (0–36) | 30 (3–126) | 4.5 (2–41+) |
| Piura et al. (1990) [31] | 1961–1988 | 200 | 2 (1) | 22 (21–23) | 41.5 (40–43) | 19.5 (19–20) |
| Plaxe et al. (1990) [32] | NA | NA | 6 | 28.5 (2–61) | NA | 10 (2–24) |
| LeRoux et al. (1991) [33] | 1980–1989 | 1,316 | 14 (1.1) | 14.5 (0–72) | NA | 3 (0.1–36) |
| Rodriguez et al. (1992) [34] | 1977–1990 | 795 | 16 (2) | NA | NA | 9 |
| Bruzzone et al. (1993) [35] | 1981–1989 | 413 | 9 (2.2) | 19 (3–36) | 26 (10–81) | 8 (1–45) |
| Salvati and Cervani (1994) [36] | 1980–1988 | NA | 4 | 21 (10–26) | NA | 28 (17–48) |
| Geisler and Geisler (1995) [37] | 1979–1992 | 479 | 16 (3.3) | 19 (2–41) | NA | 3 (1–24) |
| Cormio et al. (1995) [38] | 1982–1994 | NA | 23 | 35 (5–114) | 42 (8–133) | 5 (1–24) |
| Suzuki et al. (1999) [39] | 1982–1998 | 311 | 4 (1.3) | NA | NA | NA |
| Zhao et al. (1999) [40] | 1989–1997 | 132 | 4 (3%) | NA | NA | 10 (2–19+) |
| Kaminsky-Forrett et al. (2000) [41] | 1974–1998 | 704 | 8 (1.1) | 15 (2–80) | NA | 3 (1–12) |
| Sanderson et al. (2002) [42] | 1995–2000 | 1,222 | 13 (1.1) | 36 (6–60) | NA | 6 (2–42+) |
| Anupol et al. (2002) [43] | 1986–2000 | 1,042 | 15 (1.4) | 22 (0–53) | 38 (9–82) | 6 (0–49) |
| Kolomainen et al. (2002) [21] | 1980–2000 | 3,690 | 18 (0.5) | 46 (12–113) | NA | 7 (1–41) |
| Pothuri et al. (2002) [44] | 1989–2001 | NA | 14 | 42 (15.6–98.4) | NA | 18 (0.5–32.8) |
| Kumar et al. (2003) [45] | 1991–2001 | 658 | 18 (2.7) | 29 (0–101) | 30.5 (5–110) | 4 (1–74) |
| Li and Fu (2003) [46] | 1996–2000 | 478 | 10 (2.1) | NA | NA | 6.3 (<1–33) |
| Cohen et al. (2004) [47] | 1975–2001 | 8,225 | 72 (0.9) | 22 (0–219) | 40.5 (95% CI, 21.5–60) | 6.3 (95% CI, 5–8) |
| Tay and Rajesh (2005) [48] | 1993–2003 | 605 | 4 (0.66) | 16.5 (8–65) | NA | 19.5 |
| Pectasides et al. (2005) [49] | 1983–2004 | 1,450 | 17 (1.17) | 15.9 (1.4–70.8) | 27.4 (3–71.4) | 5.7 (0.2–22.6) |
| D'Andrea et al. (2005) [50] | 1980–2000 | NA | 11 | 21 | NA | 28 |
| Chen et al. (2005) [51] | 1985–2002 | NA | 19 | 25.2 (−0.6–112) | NA | 16.3 (0.2–111.5) |
| Kastritis et al. (2006) [52] | 1995–2004 | 267 | 8 (3) | 17.2 | 67 (95% CI, 48–85) | 22 (95% CI, 12–34) |
| Kim et al. (2007) [53] | 1996–2005 | 490 | 13 (2.7) | 28 (13–99) | NA | 7 (0–30) |
| Ogawa et al. (2008) [6] | 1985–2006 | 335 | 7 (2.1) | NA | NA | 7.3 (0.9–48.2) |
| Lee et al. (2008) [54] | 1983–2005 | 1,413 | 18 (1.3) | 28 (8–71) | NA | 14 (1–63) |
| Sehouli et al. (2010) [55] | 1981–2008 | 4,277 | 74 (1.7) | 28.8 (2.6–133.1) | 36.2 (95% CI, 33.3–39.1) | 6.2 (95% CI, 4.9–7.5) |
| Chen et al. (2011) [22] | 2000–2007 | 539 | 10 (1.9) | 24.3 (7–55) | NA | 3 (0–16) |
| Cormio et al. (2011) [56] | 1995–2010 | NA | 20 | 33 (3–70) | NA | 17.6 (0–59) |
|
| ||||||
| Total | 34,728a | 521b 413c (1.19) | 24.3 (11–46)d | 33.3 (24–67)d | 6.4 (1–28)d | |
CNS: central nervous system; OC: ovarian carcinoma; NA: not available.
aThis number represents the total number of patients with ovarian carcinoma in 29 series in which the number of ovarian carcinoma patients is available.
bThis number represents the total number of patients with brain metastases from ovarian carcinoma in all 38 series reviewed.
cThis number represents the total number (percentage) of patients with brain metastases from ovarian carcinoma in 29 series in which the number of ovarian carcinoma patients is available.
dMedian (range) of the medians. Interval between diagnosis of ovarian carcinoma and brain metastases was available in 31 series totaling 460 patients. Survival after diagnosis of ovarian carcinoma was available in 16 series totaling 236 patients. Survival after diagnosis of brain metastases was available in 36 series totaling 513 patients.